March 23, 2013
15 min watch
Save
This article is more than 5 years old. Information may no longer be current.
Adoptive T-Cell transfer
Patrick Hwu, MD, discussed recent results of an ongoing adoptive cell therapy trial, MDACC TIL ACT clinical trial, at the HemOnc Today Melanoma and Cutaneous Malignancies symposium.
Hwu highlighted a 45% response rate, adding that a lot of the patients are long-term responders, over 2 and 3 years, as of July 2012.
In addition, he said the growth of TIL does predict better response to chemotherapy but not immunotherapy; improvement in outcome in patients who group TIL does not account for the high response rates following TIL therapy; adoptive T-cell therapy is highly effective with patients with metastatic melanoma.